# US 2023/0406925 A1 · Siglec-8 binding proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406925 A1
- Document ID: US20230406925A1
- Status: Published application
- Kind: A1
- Application number: 18/361,184
- Filed: 2023-07-28
- Published: 2023-12-21
- Earliest claimed: 2022-04-22
- Assignees: Phylaxis Bioscience, LLC; Inhibrx, Inc.
- Applicants: Phylaxis Bioscience, LLC; Inhibrx, Inc.
- Inventors: Tony Dung-Ling Yao; Andrew M. Eckles; Jacob J. Gano; Bryan Becklund; Brendan P. Eckelman
- Web page: https://patentgrep.com/patent/US20230406925A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.

## Claims

### Claim 1

An VHH domain that binds Siglec-8, comprising complementarity determining region 1 (CDR1), complementarity determining region 2 (CDR2), and complementarity determining region 3 (CDR3) sequences of a VHH that comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 26, 5, 11, 16, 21, 31, 36, 130-138, 140-148, 161, 163, and 164.

### Claim 2

An VHH domain that binds Siglec-8, comprising CDR1, CDR2, and CDR3 sequences set forth in:
a) SEQ ID NOs: 46, 47, and 48, respectively, as defined according to the AbM numbering system;
b) SEQ ID NOs: 149, 150, and 151, respectively, as defined according to the Chothia numbering system;
c) SEQ ID NOs: 152, 153, and 154, respectively, as defined according to the Kabat numbering system;
d) SEQ ID NOs: 155, 156, and 157, respectively, as defined according to the Contact numbering system; or
e) SEQ ID NOs: 158, 159, and 160, respectively, as defined according to the IMGT numbering system.

### Claim 3 (depends on 2)

The VHH domain of claim 2, wherein:
a) the CDR1 comprises the amino acid sequence of SEQ ID NO: 18, 2, or 13; the CDR2 comprises the amino acid sequence of SEQ ID NO: 29 or 3; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 8, as defined according to the AbM numbering system;
b) the CDR1 comprises the amino acid sequence of SEQ ID NO: 74, 75, or 76; the CDR2 comprises the amino acid sequence of SEQ ID NO: 80 or 81; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 8, as defined according to the Chothia numbering system;
c) the CDR1 comprises the amino acid sequence of SEQ ID NO: 85, 86, or 87; the CDR2 comprises the amino acid sequence of SEQ ID NO: 92, 93, or 94; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 8, as defined according to the Kabat numbering system;
d) the CDR1 comprises the amino acid sequence of SEQ ID NO: 98, 99, or 100; the CDR2 comprises the amino acid sequence of SEQ ID NO: 104 or 105; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 110, as defined according to the Contact numbering system; or
e) the CDR1 comprises the amino acid sequence of SEQ ID NO: 114, 115, or 116;
the CDR2 comprises the amino acid sequence of SEQ ID NO: 120 or 121; and the CDR3 comprises the amino acid sequence of SEQ ID NO: 126, as defined according to the IMGT numbering system.

### Claim 4 (depends on 2)

The VHH domain of claim 2, wherein the CDR1, CDR2, and CDR3 sequences are set forth in:
a) SEQ ID NOs: 18, 29, and 8; 2, 3, and 8; 13, 3, and 8; or 18, 3, and 8, respectively, as defined according to the AbM numbering system;
b) SEQ ID NOs: 74, 80, and 8; 75, 80, and 8; 76, 80, and 8; or 76, 81, and 8, respectively, as defined according to the Chothia numbering system;
c) SEQ ID NOs: 85, 92, and 8; 86, 92, and 8; 87, 93, and 8; 87, 92, and 8; or 87, 94, and 8, respectively, as defined according to the Kabat numbering system;
d) SEQ ID NOs: 98, 104, and 110; 99, 104, and 110; 100, 104, and 110; or 100, 105, and 110, respectively, as defined according to the Contact numbering system; or
e) SEQ ID NOs: 114, 120, and 126; 115, 120, and 126; 116, 120, and 126; or 116, 121, and 126, respectively, as defined according to the IMGT numbering system.

### Claim at position 5

5-8. (canceled)

### Claim 9 (depends on 2)

The VHH domain of claim 2, comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 26, 5, 11, 16, 21, 31, 36, 130-138, 140-148, 161, 163, and 164.

### Claim 10 (depends on 2)

The VHH domain of claim 2, wherein the VHH domain is humanized.

### Claim 11

An VHH domain that binds Siglec-8, comprising CDR1, CDR2, and CDR3 sequences of a VHH that comprises the amino acid sequence of SEQ ID NO: 1, 49 or 61.

### Claim at position 9

12-22. (canceled)

### Claim 23 (depends on 2)

A polypeptide comprising the VHH domain of claim 2.

### Claim 24 (depends on 2, 23)

The polypeptide of claim 23, comprising at least two VHH domains of claim 2.

### Claim 25 (depends on 24)

The polypeptide of claim 24, wherein the two VHH domains are operably linked to each other via a peptide linker, a peptide linker comprising the amino acid sequence of SEQ ID NO: 69, or a peptide linker consisting of the amino acid sequence of SEQ ID NO: 69.

### Claim at position 13

26-27. (canceled)

### Claim 28 (depends on 24)

The polypeptide of claim 24, wherein the VHH domains comprise the same VHH amino acid sequence.

### Claim 29 (depends on 24)

The polypeptide of claim 24, wherein the polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to the amino acid sequence of SEQ ID NO: 9, 10, 12, 17, 22, 27, 32, 37, 50, 51, 56, 57, 62, or 63.

### Claim 30 (depends on 23)

The polypeptide of claim 23, further comprising a multimerization domain.

### Claim 31

A polypeptide comprising:
(i) at least two antigen-binding domains that bind Siglec-8 and a multimerization domain; or
(ii) at least three antigen-binding domains that bind Siglec-8.

### Claim at position 18

32-37. (canceled)

### Claim 38 (depends on 30)

The polypeptide of claim 30, wherein the multimerization domain is an antibody Fc region.

### Claim 39

(canceled)

### Claim 40 (depends on 38)

The polypeptide of claim 38, wherein the antibody Fc region is a human IgG1 Fc region or comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 44, 45, 65, 66, 67, or 68.

### Claim at position 22

41-43. (canceled)

### Claim 44 (depends on 38)

The polypeptide of claim 38, wherein the polypeptide comprises the structure VHH-VHH-Fc, VHH-Fc-VHH, VHH-VHH-VHH-Fc, or VHH-VHH-Fc-VHH.

### Claim 45 (depends on 44)

The polypeptide of claim 44, comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 71.

### Claim at position 25

46-47. (canceled)

### Claim 48 (depends on 30)

A protein comprising two or more polypeptides of claim 30 multimerized under physiological conditions via the multimerization domain.

### Claim 49

(canceled)

### Claim 50 (depends on 38)

A protein comprising two polypeptides of claim 38 dimerized under physiological conditions via the dimerization domain.

### Claim at position 29

51-58. (canceled)

### Claim 59 (depends on 50)

A pharmaceutical composition comprising the protein of claim 50, and a pharmaceutically acceptable carrier.

### Claim 60 (depends on 23)

An isolated nucleic acid that encodes the polypeptide of claim 23.

### Claim 61 (depends on 60)

A vector comprising the nucleic acid of claim 60.

### Claim 62 (depends on 60)

A host cell comprising the nucleic acid of claim 60.

### Claim 63 (depends on 23)

A host cell that expresses the polypeptide of claim 23.

### Claim 64 (depends on 62)

A method of producing a polypeptide or protein, the method comprising incubating the host cell of claim 62 under conditions for expression of the polypeptide or protein.

### Claim 65

(canceled)

### Claim 66 (depends on 59)

A method of treating an eosinophilic disorder or a mast cell disorder, an inflammatory disease or condition, or an allergic condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 59.

### Claim at position 38

67-73. (canceled)

### Claim 74 (depends on 50)

A method of depleting eosinophils in a subject, the method comprising administering to the subject a therapeutically effective amount of the protein of claim 50.

### Claim 75 (depends on 50)

A method of killing an eosinophil, the method comprising contacting the eosinophil with a natural killer (NK) cell in the presence of the polypeptide or protein of claim 50.

### Claim 76 (depends on 50)

A method of killing an eosinophil, the method comprising contacting the eosinophil with a macrophage in the presence of the protein of claim 50.
